EATG » Fostemsavir for highly treatment-experienced participants: 24-week phase 3 results

Fostemsavir for highly treatment-experienced participants: 24-week phase 3 results

The most important results at EACS 2017 on new pipeline compounds were the first phase 3 results for the investigational entry inhibitor fostemsavir.

As with any first drug in a new class, this data will provide hope for people with multidrug HIV resistance and whose combination is failing. For people in this situation, fostemsavir could be a life-saving drug.

Read the full publication here.

 

See also:

Share on FacebookTweet about this on TwitterShare on Google+Pin on PinterestShare on LinkedIn
Source:
HIV i-Base
News categories: Resistance, HIV treatment